HOSPITAL UNIVERSITARIO RUBER
Departamento
Centre Hospitalier Regional et Universitaire de Lille
Lila, FranciaPublicaciones en colaboración con investigadores/as de Centre Hospitalier Regional et Universitaire de Lille (1)
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710